Close menu
Brain & Behavior
Grants & Prizes
Home
Research
Illness
Addiction
Anxiety Disorders
Attention-Deficit Hyperactivity Disorder (ADHD)
Autism Spectrum Disorder (ASD)
Bipolar Disorder
Borderline Personality Disorder (BPD)
Depression
Eating Disorders
Mental Illness (General)
Obsessive-Compulsive Disorder (OCD)
Post-Traumatic Stress Disorder (PTSD)
Schizophrenia
Suicide Prevention
Other Brain-Related Illnesses
Category
Basic Research
New Technologies
Early Intervention/ Diagnostic Tools
Next Generation Therapies
Blog
Get Involved
Give
Donate Today
Make a Memorial/Tribute Gift
Create an Event/Memorial Page
Find an Event/Memorial Page
Make a Stock/Securities Gift/IRA Charitable Rollover Gift
Donate Cryptocurrency
Get Involved
Other Giving Opportunities
$1 Million Challenge Match
Planned Giving
Research Partners
Donor Advised Funds
Workplace Giving
Team Up for Research!
Sponsorship Opportunities
Watch
Healthy Minds TV
Meet the Scientist Webinars
Videos
Connect
Ask the Expert
Join Us
Home
Grants
Grant FAQs
BBRF Young Investigator Grants
BBRF Independent Investigator Grants
BBRF Distinguished Investigator Grants
Prizes & Awards
Klerman & Freedman Prizes
Outstanding Achievement Prizes
Lieber Prize for Schizophrenia Research
Maltz Prize for Schizophrenia Research
Colvin Prize for Mood Disorders Research
Ruane Prize for Child and Adolescent Psychiatric Research
Goldman-Rakic Prize for Cognitive Neuroscience Research
The Pardes Humanitarian Prize
Productive Lives Awards
Blog
About Us
Who We Are
Our Impact
FAQs
Media Center
News
Press Releases
Opinion Pieces
In the News
Multimedia Library
Media Kit
Events & Webinars
Team Up for Research! Events
Healthy Minds TV
Contact
Email Signup
Open Menu

Menu

What do you see on the horizon in the next few years as a breakthrough treatment for depression?

Go Back to the Questions

Q. What do you see on the horizon in the next few years as a breakthrough treatment for depression?

Eric J. Nestler, M.D., Ph.D. - Brain & behavior expert on anxiety and addiction research
Read Full Bio
Answer By: Eric J. Nestler, M.D., Ph.D.

Nash Family Professor of Neuroscience

Chair, Department of Neuroscience

Director, Friedman Brain Institute

Icahn School of Medicine at Mount Sinai

Several rapidly acting antidepressants are currently in clinical trial, such as ketamine. These rapidly acting agents have novel mechanisms compared to currently available antidepressants and could offer significant improvement to patients who do not fully respond to today's medications. In addition, efforts continue to identify even more antidepressant medications with novel mechanisms of action.

Learn more about Ketamine:

Tags:
Bipolar Disorder Depression
Ask an Expert

Related Articles

Precise Imaging Reveals How a Key Receptor's Signaling Is Modulated—A Spur to Improving Psychiatric and Other Drugs

READ

Posted: Thursday, May 12, 2022

Precise Imaging Reveals How a Key Receptor's Signaling Is Modulated—A Spur to Improving Psychiatric and Other Drugs

Read more
Simple Parent Questionnaire Can Help Doctors Track Mood Symptom Trajectory in Youths at High Risk for Bipolar Disorder

READ

Posted: Thursday, March 31, 2022

Simple Parent Questionnaire Can Help Doctors Track Mood Symptom Trajectory in Youths at High Risk for Bipolar Disorder

Read more
Lumateperone, an Antipsychotic, is Tested in a Phase 3 Trial for Major Depressive Episodes in Bipolar I and II Disorders

READ

Posted: Thursday, November 4, 2021

Lumateperone, an Antipsychotic, is Tested in a Phase 3 Trial for Major Depressive Episodes in Bipolar I and II Disorders

Read more
Obesity Is a Risk Factor for Brain-Structure Changes in Schizophrenia and Bipolar Disorder, 2 Studies Show

READ

Posted: Thursday, August 12, 2021

Obesity Is a Risk Factor for Brain-Structure Changes in Schizophrenia and Bipolar Disorder, 2 Studies Show

Read more